186 related articles for article (PubMed ID: 21993673)
1. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Iland H; Bradstock K; Seymour J; Hertzberg M; Grigg A; Taylor K; Catalano J; Cannell P; Horvath N; Deveridge S; Browett P; Brighton T; Chong L; Springall F; Ayling J; Catalano A; Supple S; Collins M; Di Iulio J; Reynolds J;
Haematologica; 2012 Feb; 97(2):227-34. PubMed ID: 21993673
[TBL] [Abstract][Full Text] [Related]
2. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
3. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ; Bradstock K; Supple SG; Catalano A; Collins M; Hertzberg M; Browett P; Grigg A; Firkin F; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Blood; 2012 Aug; 120(8):1570-80; quiz 1752. PubMed ID: 22715121
[TBL] [Abstract][Full Text] [Related]
4. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
5. Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial.
Röllig C; Schäfer-Eckardt K; Hänel M; Kramer M; Schaich M; Thiede C; Oelschlägel U; Mohr B; Wagner T; Einsele H; Krause SW; Bodenstein H; Martin S; Stuhlmann R; Ho AD; Bornhäuser M; Ehninger G; Schuler U; Platzbecker U
Ann Hematol; 2015 Apr; 94(4):557-63. PubMed ID: 25366167
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
7. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
Xu LW; Su YZ; Tao HF
Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
[TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Henzan H; Takase K; Kamimura T; Mori Y; Yoshimoto G; Iwasaki H; Nagafuji K; Ogawa R; Eto T; Uchida N; Fujisaki T; Kato K; Minami M; Kikushige Y; Akashi K; Miyamoto T;
Int J Hematol; 2020 Sep; 112(3):349-360. PubMed ID: 32524309
[TBL] [Abstract][Full Text] [Related]
9. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
[TBL] [Abstract][Full Text] [Related]
10. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
Sanz MA; Martín G; González M; León A; Rayón C; Rivas C; Colomer D; Amutio E; Capote FJ; Milone GA; De La Serna J; Román J; Barragán E; Bergua J; Escoda L; Parody R; Negri S; Calasanz MJ; Bolufer P;
Blood; 2004 Feb; 103(4):1237-43. PubMed ID: 14576047
[TBL] [Abstract][Full Text] [Related]
11. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F
Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858
[TBL] [Abstract][Full Text] [Related]
12. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acute promyelocytic leukaemia using a combination of all-trans retinoic acid and chemotherapy.
Koh LP; Goh YT; Teoh G; Tan P
Ann Acad Med Singap; 2001 Jul; 30(4):401-8. PubMed ID: 11503549
[TBL] [Abstract][Full Text] [Related]
14. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
15. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.
Sanz MA; Martín G; Rayón C; Esteve J; González M; Díaz-Mediavilla J; Bolufer P; Barragán E; Terol MJ; González JD; Colomer D; Chillón C; Rivas C; Gómez T; Ribera JM; Bornstein R; Román J; Calasanz MJ; Arias J; Alvarez C; Ramos F; Debén G
Blood; 1999 Nov; 94(9):3015-21. PubMed ID: 10556184
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up.
Avvisati G; Petti MC; Lo-Coco F; Vegna ML; Amadori S; Baccarani M; Cantore N; Di Bona E; Ferrara F; Fioritoni G; Gallo E; Invernizzi R; Lazzarino M; Liso V; Mariani G; Ricciuti F; Selleri C; Sica S; Veneri D; Mandelli F;
Blood; 2002 Nov; 100(9):3141-6. PubMed ID: 12384411
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
Schlenk RF; Germing U; Hartmann F; Glasmacher A; Fischer JT; del Valle y Fuentes F; Götze K; Pralle H; Nerl C; Salwender H; Grimminger W; Petzer A; Hensel M; Benner A; Zick L; Döhner K; Fröhling S; Döhner H;
Leukemia; 2005 Jun; 19(6):978-83. PubMed ID: 15843821
[TBL] [Abstract][Full Text] [Related]
18. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia.
Sanz MA; Vellenga E; Rayón C; Díaz-Mediavilla J; Rivas C; Amutio E; Arias J; Debén G; Novo A; Bergua J; de la Serna J; Bueno J; Negri S; Beltrán de Heredia JM; Martín G
Blood; 2004 Dec; 104(12):3490-3. PubMed ID: 15292063
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
20. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.
Mandelli F; Diverio D; Avvisati G; Luciano A; Barbui T; Bernasconi C; Broccia G; Cerri R; Falda M; Fioritoni G; Leoni F; Liso V; Petti MC; Rodeghiero F; Saglio G; Vegna ML; Visani G; Jehn U; Willemze R; Muus P; Pelicci PG; Biondi A; Lo Coco F
Blood; 1997 Aug; 90(3):1014-21. PubMed ID: 9242531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
